SCHEMBL20965377

SCHEMBL20965377

Cc1cc(CSc2ccccc2C(=O)N2CCN(c3cccc(O)c3)CC2)on1

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.58
ALDH1A1 P00352 3/20 0.58
SMN1; SMN2 Q16637 3/20 0.58
TSHR P16473 2/20 0.58
MEN1 O00255 5/20 0.49
KMT2A Q03164 5/20 0.49
HTT P42858 2/20 0.49
MAPK1 P28482 1/20 0.49
TP53 P04637 1/20 0.48
NPC1 O15118 4/20 0.47
RAB9A P51151 4/20 0.47
MAPT P10636 2/20 0.43
PKM P14618 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MYC P01106 1/20 0.42
RXFP1 Q9HBX9 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20964553 0.91 ALDH1A1 (0.69) LMNAALDH1A1SMN1; SMN2TSHRMEN1
SCHEMBL20964665 0.91 LMNA (0.62) LMNAALDH1A1SMN1; SMN2TSHRMEN1
SCHEMBL20964599 0.86 LMNA (0.59) LMNAALDH1A1SMN1; SMN2TSHRMEN1
SCHEMBL20964636 0.85 SMN1; SMN2 (0.53) LMNAALDH1A1SMN1; SMN2TSHRMEN1
SCHEMBL20964645 0.84 LMNA (0.82) LMNAALDH1A1SMN1; SMN2TSHRMEN1
SCHEMBL20964683 0.84 LMNA (0.53) LMNAALDH1A1SMN1; SMN2TSHRKMT2A
SCHEMBL20964637 0.84 LMNA (0.60) LMNAALDH1A1SMN1; SMN2TSHRMEN1
SCHEMBL20965289 0.83 ALDH1A1 (0.67) LMNAALDH1A1SMN1; SMN2TSHRMEN1
SCHEMBL20964548 0.82 ALDH1A1 (0.59) LMNAALDH1A1SMN1; SMN2TSHRMEN1
SCHEMBL20964655 0.81 LMNA (0.52) LMNAALDH1A1SMN1; SMN2TSHRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10851096-B2 Aryl and heteroaryl amides for use as anti-proliferative, anti-thrombotic, and anti-viral agents RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2020-12-01 US disclosed
US-20190127361-A1 Therapeutic Compounds RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2019-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190127361-A1 Therapeutic Compounds SDHA, SLC10A1, SERPINC1 LMNA 1413/4885ALDH1A1 141/4885SMN1; SMN2 263/4885
US-10851096-B2 Aryl and heteroaryl amides for use as anti-proliferative, anti-thrombotic, and anti-viral agents SERPINC1, F12, RPL35 LMNA 897/4885ALDH1A1 870/4885SMN1; SMN2 2477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.